Equibles does not estimate personal net worth.
Get an email with a short summary when PureTech Health plc publishes a filing, an earnings call transcript or a press release.
Get PTCHF alertsBrenton L. Saunders is recorded as CEO at PureTech Health plc (PTCHF) and Chairman at SkinHealth Systems Inc. (SKIN). The newest filing on record that lists Brenton L. Saunders as Chairman at SkinHealth Systems Inc. (SKIN) is dated April 24, 2026. Earlier roles on record: Board Member at BridgeBio Pharma, Inc. (BBIO) until March 6, 2023, CEO and Board Member at Bausch & Lomb Corp (BLCO) until October 12, 2026 and Board Member at Cisco Systems, Inc. (CSCO) until February 21, 2023. Bausch & Lomb Corp reported in an 8-K filed October 13, 2026 that Brenton L. Saunders resigned as each and every other position I hold with the Company or any of its subsidiaries or affiliates, whether as a director, manager,, effective October 12, 2026. Bausch & Lomb Corp reported in an 8-K filed October 13, 2026 that Brenton L. Saunders resigned as director, effective October 12, 2026. Bausch & Lomb Corp reported in an 8-K filed October 13, 2026 that Brenton L. Saunders resigned as Chief Executive Officer, effective October 12, 2026. Equibles holds 6 filed executive changes naming Brenton L. Saunders; each is listed under recent activity with its source filing. The proxy statement of Bausch & Lomb Corp reports total compensation of $32,194,326 for Brenton L. Saunders in fiscal 2025, including a base salary of $1,600,000. Disclosed compensation is on record for 5 fiscal years. Brenton L. Saunders has spoken on 3 earnings calls across 1 company, most recently for SkinHealth Systems Inc. on February 22, 2022. SkinHealth Systems Inc. is classified in the Household & Personal Products industry within the Consumer Defensive sector. PureTech Health plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at SkinHealth Systems Inc. includes Clinton Carnell (CEO), Clinton E. Carnell (CEO and Board Member), Pedro Malha (CEO and Board Member) and 7 others.
“Pursuant to our mutual agreement, I irrevocably resign, effective as of the Separation Date, from each and every other position I hold with the Company or any of its subsidiaries or affiliates, whether as a director, manager, officer, trustee, administrator, fiduciary, committee member, authorized signatory or in any similar capacity, and from any position I hold at the request or on behalf of the Company or any of its subsidiaries or affiliates with any other entity.”
“I, Brenton L. Saunders, hereby acknowledge, confirm and agree as follows: 1. Pursuant to our mutual agreement as memorialized in the Separation Agreement dated October 11, 2026, by and between Bausch + Lomb Corporation (the “Company”) and Brenton L. Saunders, I irrevocably resign from the offices of Chief Executive Officer of the Company and as a director from the Board of Directors of the Company (the “Board”), and from my employment with the Company, effective as of 12:01 a.m. Eastern Time on Monday, October 12, 2026 (the “Separation Date”).”
“Thank you for joining us for a discussion of our fourth-quarter and full-year 2021 results. I would now like to formally introduce Andrew to all of you and welcome him to the Beauty Health team.”
“As I’m sure you saw on today’s press release, I will be stepping into the role as the company's interim CEO effective January 1, 2022. As part of this transition, Clint will remain CEO through year-end at which point I will assume additional responsibilities of the CEO until a permanent successor is named.”
“Thank you, Dawn, and thank you for joining our very first earnings call as a public company. Last week, we successfully closed our business combination and became The Beauty Health Company.”
Start not stated–present
Last confirmed April 24, 2026
2024-05-29–2026-10-12
2017-01-01–2023-02-21
Start not stated–2022-05-12
Last confirmed by a filing; no departure on record
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Start not stated–2023-03-06
Start not stated–2026-10-12
Household & Personal Products · Consumer Defensive
Chairman
BLCO
Medical Instruments & Supplies · Healthcare
CEO, Board Member
2024-05-29–2026-10-12
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bausch & Lomb Corp (BLCO) | Chairman of the Board and Chief Executive Officer | $1,600,000 | $32,194,326 |
| 2024 | Bausch & Lomb Corp (BLCO) | Chairman of the Board and Chief Executive Officer | $1,600,000 | $23,860,756 |
| 2023 | Bausch & Lomb Corp (BLCO) | Chairman of the Board and Chief Executive Officer | $1,396,923 | $45,309,051 |
| 2022 | SkinHealth Systems Inc. (SKIN) | Chairman and Former Interim Chief Executive Officer and Former Executive Chairman | $479,988 | $3,464,119 |
| 2021 | SkinHealth Systems Inc. (SKIN) | Chairman and Former Interim Chief Executive Officer and Former Executive Chairman | — | $14,942,115 |
